• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Iranian Journal of Pharmaceutical Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 18 (2019)
Volume Volume 17 (2018)
Issue Special Issue 2
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Special Issue 1
Issue Issue 1
Volume Volume 16 (2017)
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
Abbasi, S., Farsaei, S., Ghasemi, D., Mansourian, M. (2018). Potential Role of Exogenous Melatonin Supplement in Delirium Prevention in Critically Ill Patients: A Double-Blind Randomized Pilot Study. Iranian Journal of Pharmaceutical Research, 17(4), 1571-1580. doi: 10.22037/ijpr.2018.2312
Saeed Abbasi; Shadi Farsaei; Dorsa Ghasemi; Marjan Mansourian. "Potential Role of Exogenous Melatonin Supplement in Delirium Prevention in Critically Ill Patients: A Double-Blind Randomized Pilot Study". Iranian Journal of Pharmaceutical Research, 17, 4, 2018, 1571-1580. doi: 10.22037/ijpr.2018.2312
Abbasi, S., Farsaei, S., Ghasemi, D., Mansourian, M. (2018). 'Potential Role of Exogenous Melatonin Supplement in Delirium Prevention in Critically Ill Patients: A Double-Blind Randomized Pilot Study', Iranian Journal of Pharmaceutical Research, 17(4), pp. 1571-1580. doi: 10.22037/ijpr.2018.2312
Abbasi, S., Farsaei, S., Ghasemi, D., Mansourian, M. Potential Role of Exogenous Melatonin Supplement in Delirium Prevention in Critically Ill Patients: A Double-Blind Randomized Pilot Study. Iranian Journal of Pharmaceutical Research, 2018; 17(4): 1571-1580. doi: 10.22037/ijpr.2018.2312

Potential Role of Exogenous Melatonin Supplement in Delirium Prevention in Critically Ill Patients: A Double-Blind Randomized Pilot Study

Article 39, Volume 17, Issue 4, Autumn 2018, Page 1571-1580  XML PDF (426.1 K)
Document Type: Research article
DOI: 10.22037/ijpr.2018.2312
Authors
Saeed Abbasi1; Shadi Farsaei email 2; Dorsa Ghasemi3; Marjan Mansourian4
1Anesthesiology and Critical Care Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2Department of Clinical Pharmacy and Pharmacy Practice, Isfahan Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
3Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
4Department of Biostatistics, Faculty of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract

Critically ill patients often suffer from disturbance of sleep-wake cycle and consequently delirium development, in intensive care units (ICU). In this study, we aimed to evaluate the effect of exogenous melatonin on delirium development and its related adverse sequelae in the subgroup of medical and surgical ICU patients. We performed a double-blind placebo-controlled randomized pilot study in adult patients admitted to the ICU. Recruited patients according to the considered inclusion criteria were randomized into treatment or placebo groups. Melatonin or placebo was administered in the first 24 h after admission, for 5 consecutive days. Incidence of delirium within 8 days of admission was reported as primary outcome in the different subgroups, and other pertinent clinical characteristics were evaluated as secondary outcomes. Out of the total of 172 patients assigned for the 2 study groups, 70 patients in placebo group and also 67 in melatonin group completed the study. We observed no therapeutic effect of melatonin on delirium prevention in ICU patients (percent of delirium in melatonin versus placebo group were 4.5% and 1.4% respectively). However, our findings indicated that melatonin might be more useful in preventing delirium development in medical ICU patients as compared to the surgical ICU patients. There were no intergroup differences in secondary outcomes with the follow-up ending on May 2016. Our findings suggested melatonin might be a potential option for prevention of delirium in medical ICU patients.
Keywords
Melatonin; Delirium; Critical care; Clinical trial
Main Subjects
Pharmacotherapy (Clinical Pharmacy)
Statistics
Article View: 268
PDF Download: 498
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Statistics

Journal Management System. Designed by sinaweb.